Regulatory & Reimbursement
FDA Output, September 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in September 2026. Updated September 30.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Medtech Capital Matters
MedTech Capital Matters September 2026
Recent private financings of medtech companies. The summer was by no means sleepy, with at least 22 venture capital deals.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: New ARPA Grants for Cardiology AI
New funding from for the agency’s ADVOCATE program. Excerpted from Pathways Picks September 9: FDA Taps Tech Chief, Key Staffer Departs, EU Procurement Reform, and More.